3D185, which simultaneously targets FGFR and CSF-1R, is expected to both inhibit tumor cells and remodel the tumor microenvironment to synergistically antagonize tumors and delay the development of resistance to FGFR inhibitors alone. The gene discussed is CSF1R; the disease is neoplasm.